P.06.5 DIABETES AND GASTROINTESTINAL DISORDERS: THE EFFECT OF INTESTINAL METHANE PRODUCTION ON GLYCEMIC CONTROL

V. Cesario , T.A. Di Rienzo , D. Pitocco , M. Campanale
Digestive and Liver Disease 45

2013
P.06.25 THE PREVALENCE OF SMALL BACTERIAL OVERGROWTH AND GAS PRODUCTION IN PATIENTS WITH SPINA BIFIDA

G. Bruno , C. Rendeli , V. Paolucci , S. Triarico
Digestive and Liver Disease 45

2013
P.04.7 PREVALENCE OF H. PYLORI INFECTION AMONG PATIENTS COMING FROM DIFFERENT COUNTRIES AND LIVING IN ROME AREA

C. Petruzziello , V. Tesori , C. Graziani , F. Franceschi
Digestive and Liver Disease 48

2016
2016
P.1.148: RIFAXIMIN TREATMENT FOR SMALL INTESTINAL BACTERIAL OVERGROWTH IN CHILDREN WITH IRRITABLE BOWEL SYNDROME

E. Scarpellini , V. Giorgio , M. Gabrielli , S. Filoni
Digestive and Liver Disease 43

2011
P.1.181: ACCURACY OF CO2 CORRECTED H2 AND CH4 VALUES IN BREATH TESTS

M. Campanale , E. Scarpellini , A. Tortora , F. Bertucci
Digestive and Liver Disease 43

2011
P.11.10 INTESTINAL PERMEABILITY IN NICKEL ALLERGY

E. Scalpellini , E. Nucera , M.C. Campanale , V. Valenza
Digestive and Liver Disease 44 S157

2012
P.07.20 A LOWER QUALITY OF LIFE IN PATIENTS WITH FUNCTIONAL BOWEL DISORDERS COMPARED TO THOSE WITH GASTRIC DYSPEPSIA

G. Gigante , F. Bertucci , V. Ojetti , A. Tortora
Digestive and Liver Disease 44

2012
P.07.2 EFFICACY OF RIFAXIMIN IN THE TREATMENT OF COLONIC BACTERIAL OVERGROWTH IN IBS PATIENTS: PRELIMINARY RESULTS

A. Tortora , M. Gabrielli , F. Purchiaroni , V. Ojetti
Digestive and Liver Disease 44

2012
P.07.12 HIGH LEVEL OF METHANOGENIC FLORA IN PATIENTS AFFECTED BY POORLY CONTROLLED TYPE I DIABETES

T.A. Di Rienzo , V. Cesario , M.C. Campanale , F. Barbaro
Digestive and Liver Disease 44

2012
P.07.9 THE PREVALENCE OF “H2 NON PRODUCER” IN IBS POPULATION

G. Bruno , F. D'Aversa , V. Gerardi , T.A. Di Rienzo
Digestive and Liver Disease 44

2012
The effect of oral administration of Lactobacillus GG on antibiotic‐associated gastrointestinal side‐effects during Helicobacter pylori eradication therapy

A. Armuzzi , F. Cremonini , F. Bartolozzi , F. Canducci
Alimentary Pharmacology & Therapeutics 15 ( 2) 163 -169

450
2001
Rifabutin‐based Helicobacter pylori eradication ‘rescue therapy’

F. Canducci , V. Ojetti , P. Pola , G. Gasbarrini
Alimentary Pharmacology & Therapeutics 15 ( 1) 143 -143

88
2001
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.

E. C. Nista , G. Cammarota , A. Gasbarrini , S. Di Caro
Alimentary Pharmacology & Therapeutics 16 ( 3) 527 -532

48
2002
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria.

V. Ojetti , A. Armuzzi , A. De Luca , E. Nucera
International Archives of Allergy and Immunology 125 ( 1) 66 -72

24
2001
Beta-lactamase inhibitor enhances Helicobacter pylori eradication rate.

V. Ojetti , A. Migneco , M. A. Zocco , E. C. Nista
Journal of Internal Medicine 255 ( 1) 125 -129

16
2004
H pylori re-infection in type 1 diabetes: a 5 years follow-up.

V. Ojetti , A. Migneco , E.C. Nista , G. Gasbarrini
Digestive and Liver Disease 39 ( 3) 286 -287

9
2007